CABA Cabaletta Bio, Inc.
Price Chart
Executive Summary
Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51% dilution from the prior ~100.5M shares outstanding. The filing also disclosed a preliminary cash balance of ~$117M as of March 31, 2026, and the company reported Q4 2025 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39. The capital raise extends the cash runway into mid-2027 to fund clinical development of rese-cel, but the massive dilution and lack of revenue fundamentally overshadow the pipeline progress.
Key Financial Metrics
Actionable Insight
The massive ~51% dilution from this offering will pressure the stock near-term. Monitor the stock for potential further downside as the market absorbs the new shares. The cash runway extension into mid-2027 is positive for the pipeline, but the dilution overhang and lack of near-term revenue catalysts suggest continued weakness.
Key Facts
- Priced underwritten offering of 51,725,000 shares at $2.90 per share, raising ~$150M in gross proceeds (~$141M net)
- Offering represents ~51% increase in shares outstanding from ~100.5M to ~152.2M shares
- Q4 2025 EPS of -$0.40 missed consensus of -$0.39 by 3.1%
- Preliminary cash balance of ~$117M as of March 31, 2026
- Net proceeds extend cash runway into mid-2027 for rese-cel clinical development and manufacturing scale-up
- No revenue reported; company is a pre-commercial biotechnology firm
Financial Impact
~$141M net proceeds from offering; ~51% dilution; Q4 2025 net loss of $41.9M
Risk Factors
- Immediate and significant dilution of ~51% from the offering
- No revenue and ongoing operating losses; net loss of $167.9M in FY2025
- Clinical-stage risk; rese-cel may fail in pivotal trials or face regulatory delays
- Cash runway only into mid-2027; may require additional capital before reaching profitability
Market Snapshot
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202446 |
| Document: d145767dex992.htm | 0001193125-26-202446 |
| Document: d145767d8k.htm | 0001193125-26-202446 |
| Document: d145767dex991.htm | 0001193125-26-202446 |
| Document: d145767dex51.htm | 0001193125-26-202446 |
| Document: 0001193125-26-202446-index-headers.html | 0001193125-26-202446 |
| Document: 0001193125-26-202446-index.html | 0001193125-26-202446 |
| Document: 0001193125-26-202446.txt | 0001193125-26-202446 |
| 8-K Data (Synthetic) | 0001193125-26-202446 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
8-K
| $3.58 $3.51 | ▼ −1.96% | ▼ −2.35% | $3.22 (−10.06%) |
|
Jun 1, 2026
8d ago
|
DEFA14A
| $3.67 $3.68 | ▲ +0.27% | ▲ +0.13% | $3.22 (−12.26%) |
|
May 14, 2026
26d ago
|
8-K
| $3.61 $3.31 | ▲ +8.31% | ▲ +7.08% | $3.22 (+10.80%) |
|
May 14, 2026
26d ago
|
Press Release
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.22 (−10.80%) |
|
May 14, 2026
26d ago
|
8-K
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.22 (−10.80%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.22 (+15.93%) |
|
May 4, 2026
5w ago
|
424B5
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.22 (+15.93%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▲ +8.36% | ▲ +7.56% | $3.22 (−15.93%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $2.86 $2.78 | ▼ −2.80% | ▼ −2.79% | $3.22 (+12.59%) |
|
Apr 20, 2026
7w ago
|
8-K
| $3.31 $3.13 | ▼ −5.29% | ▼ −4.64% | $3.22 (−2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access